Enrolling by invitation

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

I4V-MC-JAIX - ClinicalTrials.gov - NCT03559270

This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081).
How long will I be in the trial?
This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.
Email
Enrolling by invitation

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

I4V-MC-JAIX - ClinicalTrials.gov - NCT03559270

This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081).
How long will I be in the trial?
This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.
Email

Key Requirements

Age :

18+

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participants must have completed at least 16 weeks of treatment in study JAIW prior to discontinuation

Female participants must not be pregnant or breastfeeding

Participants must be willing to commit to using birth control for the duration of the study, unless pregnancy is not possible for the participant or the participants female sexual partner

Participants must NOT

Participants must not be enrolled in other studies that may not be compatible with study JAIX.

Participants must not have uncontrolled high blood pressure, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema)

What the trial is testing?

Baricitinib

Could I receive a Placebo?

no

Enrollment Goal

300

Trial Dates

June 2018 - December 2021

Trial Phase

3

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

18+

Sex

All

Participants must

Participants must have completed at least 16 weeks of treatment in study JAIW prior to discontinuation

Female participants must not be pregnant or breastfeeding

Participants must be willing to commit to using birth control for the duration of the study, unless pregnancy is not possible for the participant or the participants female sexual partner

Participants must NOT

Participants must not be enrolled in other studies that may not be compatible with study JAIX.

Participants must not have uncontrolled high blood pressure, heart attack, chest pain, stroke, heart failure or any other serious or unstable disease or infection

Trial Summary

Conditions the trial is for

Atopic Dermatitis (Eczema)

What the trial is testing?

Baricitinib

Could I receive a Placebo?

no

Enrollment Goal

300

Trial Dates

June 2018 - December 2021

Trial Phase

3

Not the right fit? Sign up to receive updates on new trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Atopic Dermatitis (Eczema) Resources

Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?